En Carta Diagnostics raised €5 million in private financing to advance regulatory clearances for its molecular point-of-care Lyme disease test and other pipeline products in Europe and the U.S. The company said it is targeting FDA and European authorization pathways and plans to ramp manufacturing capacity through partner Circum Medical. The fundraise includes €3 million in equity investments led by Blue Forest Ventures, Ring Capital, CentraleSupélec Venture and others, plus €2 million of nondilutive funding from Bpifrance. En Carta also cited a prior U.S. FDA breakthrough device designation for the EC Pocket Lyme test. For diagnostics developers, this is a practical step toward commercialization readiness—especially for non-lab settings—where regulatory and manufacturing bottlenecks often determine speed-to-market.